VALBONNE, France--(BUSINESS WIRE)--Regulatory News:
TxCell SA (FR0010127662 – TXCL) (Paris:TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, will release its consolidated financial results for the first half of 2016 and will provide an update on its strategy and perspectives on Tuesday, September 27, post-market.
A conference call and live webcast will be held on Wednesday, September 28 at 3:30pm CET in English. The conference call will be followed by a Q&A session.
Investors and analysts may participate via the following number: +33 (0) 1 72 00 15 10 / PIN Code: 20587658#
The webcast can be followed live online via the link:
Following the call, a replay will be available for 90 days. To listen to
the replay, please dial:
+33 (0)1 72 00 15 00 / 303497#
About TxCell – www.txcell.com
TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical-stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated.
TxCell is developing two proprietary technology platforms, ASTrIA and ENTrIA. ASTrIA is composed of autologous antigen-specific Type 1 Tregs. Ovasave®, TxCell’s lead drug-candidate originating from the ASTrIA platform, is currently in a phase IIb clinical trial in refractory Crohn’s disease patients. ENTrIA is composed of Chimeric Antigen Receptor engineered FoxP3+ regulatory T cells (CAR-Treg). In this area, TxCell is pursuing two CAR-Treg development programs in collaboration with leading European research institutions: one targeting Lupus Nephritis with Ospedale San Raffaele in Milan and the other targeting Bullous Pemphigoid with the Lübeck Institute of Experimental Dermatology.
Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 49 employees.
Financial and business conferences
|Oct 5-7, 2016||Cell & Gene Meeting on the Mesa||La Jolla (US)|
|Oct 5-6, 2016||European Large & Midcap Event||Paris (France)|
|Oct 26, 2016||GGS Equity Forum||Heilbronn (Germany)|
|Nov 3, 2016||ARM EU Advanced Therapies Investor Day||London (UK)|
|Nov 7-9, 2016||BIO Europe||Cologne (Germany)|
|Nov 18-19, 2016||Actionaria||Paris (France)|
|Nov 21-23, 2016||German Equity Forum||Frankfurt (Germany)|
|Sept 30-Oct 2, 2016||ISCT North America Regional Meeting||Memphis (US)|
|Oct 10-11, 2016||Adoptive T-cell Therapy Summit Europe 2016||London (UK)|
|Oct 15-19, 2016||United European Gastroenterology Week 2016||Vienna (Austria)|
|Oct 18-21, 2016||
European Society of Gene and Cell Therapy
|Nov 29-30, 2016||Cell Therapy Manufacturing & Gene Therapy Congress||Amsterdam (NL)|
Disclaimer – TxCell
This press release contains certain forward-looking statements relating to the business of TxCell, which shall not be considered per se as historical facts, including TxCell’s ability to develop, market, commercialize and achieve market acceptance for specific products, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements, needs for additional financing. In addition, even if the actual results or development of TxCell are consistent with the forward-looking statements contained in this press release, those results or developments of TxCell may not be indicative of their in the future.
In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. Although the management of TxCell believes that these forward-looking statements are reasonably made, they are based largely on the current expectations of TxCell as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of TxCell could be affected by, among other things, uncertainties involved in the development of the Company’s products, which may not succeed, or in the delivery of TxCell’s products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affects TxCell capacity to commercialize the products it develops, as well as, any other risk and uncertainties developed or identified in any public documents filed by TxCell with the AMF, included those listed in chapter 4 “Risk factors” of the 2015 document de référence approved by the AMF on May 24, 2016 under number R.16-048. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be “accurate, precise and fairly presented“), TxCell is providing the information in these materials as of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.